Telix Pharmaceuticals Ltd Ordinary Shares TLX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLX is a good fit for your portfolio.
News
-
Q1 2024 Revenue and Business Update
-
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
-
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
-
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
-
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
-
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
-
Appointment of Dr Darren Patti to Group Chief Operating Officer
-
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
Trading Information
- Previous Close Price
- A$14.88
- Day Range
- A$14.70–15.01
- 52-Week Range
- A$8.20–15.01
- Bid/Ask
- A$15.75 / A$14.17
- Market Cap
- A$4.93 Bil
- Volume/Avg
- 1.7 Mil / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 117.39
- Price/Sales
- 9.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney), and glioblastoma (brain) cancer. Geographically, It operates through two reportable segments Commercial operations which include Commercial sales of Illuccix® and other products after obtaining regulatory approvals and Product development includes Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from license agreements before commercialization and research and development services. It operates in Australia, the United States, Belgium, and Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- —
- Website
- https://www.telixpharma.com
Comparables
Valuation
|
Metric
|
TLX
|
CRNX
|
NAMS
|
|---|---|---|---|
Price/Earnings (Normalized) | 117.39 | — | — |
Price/Book Value | 32.41 | 5.33 | 6.29 |
Price/Sales | 9.58 | 609.51 | 128.23 |
Price/Cash Flow | 199.25 | — | — |
Price/Earnings
TLX
CRNX
NAMS
Financial Strength
|
Metric
|
TLX
|
CRNX
|
NAMS
|
|---|---|---|---|
Quick Ratio | 1.19 | 12.92 | 6.86 |
Current Ratio | 1.43 | 13.07 | 6.95 |
Interest Coverage | 1.15 | — | — |
Quick Ratio
TLX
CRNX
NAMS
Profitability
|
Metric
|
TLX
|
CRNX
|
NAMS
|
|---|---|---|---|
Return on Assets (Normalized) | 3.71% | −38.81% | −34.73% |
Return on Equity (Normalized) | 11.73% | −44.79% | −39.45% |
Return on Invested Capital (Normalized) | 18.08% | −45.62% | −41.57% |
Return on Assets
TLX
CRNX
NAMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lxvmkpxzh | Fmk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Twpdnsv | Tbcdbgv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mzbgzxl | Qppsn | $97.8 Bil | |
MRNA
| Moderna Inc | Phkjlkdvn | Jwdr | $41.3 Bil | |
ARGX
| argenx SE ADR | Ctmrxsfjf | Htt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cmkpfkty | Cnjyp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kdjqssr | Jlvznp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rldfmfwj | Glxth | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wzvstbxnb | Tstkxt | $12.5 Bil | |
INCY
| Incyte Corp | Ngrttyz | Srskb | $11.6 Bil |